CTLA-4 monoclonal antibody clears Treg in tumor effectively through FcR mediated ADCC (antibody-dependent cell-mediated cytotoxicity), thus relieving immunosuppressive of Treg to achieve anti-tumor (42–44). The gene discussed is CTLA4; the disease is neoplasm.